文献速递血管炎

根据ANCA状态对肉芽肿性多血管炎亚型进行的比较研究:来自法国血管炎研究组登记处的数据

Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry.
PubMed 文献 · RMD Open · 2022-01-01

该研究基于法国血管炎研究组登记处727例新诊断的肉芽肿性多血管炎(GPA)患者,比较ANCA阴性、MPO-ANCA阳性与PR3-ANCA阳性三组的诊断特征与结局。ANCA阴性患者较ANCA阳性者更多为局限性疾病且肾脏受累较少,但无复发生存期(RFS)和总生存期(OS)相当;MPO-ANCA阳性者RFS与PR3-ANCA阳性者相似但OS较低,归因于年龄较大;PR3-ANCA阳性者RFS低于另两组联合,但仅比较PR3与MPO-ANCA阳性时差异未持续。

要点

  • ANCA阴性GPA较ANCA阳性者更多为局限性疾病(17.7% vs 5.8%)且肾脏受累较少(35.5% vs 58.9%),RFS和OS相当。
  • MPO-ANCA阳性者较PR3-ANCA阳性和ANCA阴性者更多为女性(52.9% vs 42.1%)、年龄更大(59.8 vs 51.9岁)、肾脏受累更多(65.5% vs 55.2%),关节痛、紫癜和眼受累较少。
  • PR3-ANCA阳性者RFS显著低于ANCA阴性和MPO-ANCA阳性联合组,但仅比较PR3与MPO-ANCA阳性时差异未持续。

核心结论

  • 基于该大型队列,ANCA阴性较ANCA阳性患者更常见局限性疾病但RFS和OS相似;MPO-ANCA阳性者RFS相似但OS较低归因于年龄较大;PR3-ANCA阳性GPA患者RFS低于另两亚型联合但仅比较PR3与MPO-ANCA阳性时差异未持续。

研究设计与样本

  • 研究基于法国血管炎研究组登记处新诊断的GPA患者,比较ANCA阴性、MPO-ANCA阳性或PR3-ANCA阳性三组的诊断特征与结局,患者符合美国风湿病学会标准及/或Chapel Hill会议共识命名。

主要发现

  • 727例GPA中,ANCA阴性62例(8.5%),MPO-ANCA阳性119例(16.4%),PR3-ANCA阳性546例(75.1%)。
  • ANCA阴性患者较PR3-ANCA阳性或MPO-ANCA阳性患者显著更多为局限性疾病(17.7% vs 5.8%)且肾脏受累较少(35.5% vs 58.9%),RFS和OS相当。
  • MPO-ANCA阳性较PR3-ANCA阳性和ANCA阴性患者显著更多为女性(52.9% vs 42.1%)、年龄更大(59.8 vs 51.9岁)、肾脏受累更多(65.5% vs 55.2%)、关节痛较少(34.5% vs 55.1%)、紫癜较少(8.4% vs 17.1%)、眼受累较少(18.5% vs 28.4%)。
  • MPO-ANCA阳性者RFS与PR3-ANCA阳性者相似但OS在年龄校正前较低。
  • PR3-ANCA阳性患者RFS显著低于ANCA阴性和MPO-ANCA阳性联合组,OS在年龄校正前较高;PR3-ANCA阳性独立预测所有GPA联合形式的复发,但仅比较PR3-ANCA阳性与MPO-ANCA阳性患者时未预测。

关键数值与推荐

  • ANCA阴性患者局限性疾病比例为17.7%,PR3-ANCA阳性或MPO-ANCA阳性患者为5.8%(p<0.05)。
  • ANCA阴性患者肾脏受累比例为35.5%,PR3-ANCA阳性或MPO-ANCA阳性患者为58.9%(p<0.05)。
  • MPO-ANCA阳性患者女性比例为52.9%,PR3-ANCA阳性和ANCA阴性患者为42.1%(p<0.05)。
  • MPO-ANCA阳性患者年龄为59.8岁,PR3-ANCA阳性和ANCA阴性患者为51.9岁(p<0.05)。
  • MPO-ANCA阳性患者肾脏受累比例为65.5%,PR3-ANCA阳性和ANCA阴性患者为55.2%(p<0.05);关节痛比例为34.5% vs 55.1%,紫癜比例为8.4% vs 17.1%,眼受累比例为18.5% vs 28.4%(均p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether antineutrophil cytoplasm antibody (ANCA)-negative and myeloperoxidase (MPO)-ANCA-positive granulomatosis with polyangiitis (GPA) differ from proteinase-3 (PR3)-ANCA-positive GPA. METHODS: Diagnostic characteristics and outcomes of newly diagnosed French Vasculitis Study Group Registry patients with ANCA-negative, MPO-ANCA-positive or PR3-ANCA-positive GPA satisfying American College of Rheumatology criteria and/or Chapel Hill Conference Consensus Nomenclature were compared. RESULTS: Among 727 GPA, 62 (8.5%) were ANCA-negative, 119 (16.4%) MPO-ANCA-positive and 546 (75.1%) PR3-ANCA-positive. ANCA-negative patients had significantly (p<0.05) more limited disease (17.7% vs 5.8%) and less kidney involvement (35.5% vs 58.9%) than those PR3-ANCA-positive or MPO-ANCA-positive, with comparable relapse-free (RFS) and overall survival (OS). MPO-ANCA-positive versus PR3-ANCA-positive and ANCA-negative patients were significantly more often female (52.9% vs 42.1%), older (59.8 vs 51.9 years), with more frequent kidney involvement (65.5% vs 55.2%) and less arthralgias (34.5% vs 55.1%), purpura (8.4% vs 17.1%) or eye involvement (18.5% vs 28.4%); RFS was similar but OS was lower before age adjustment. PR3-positive patients' RFS was significantly lower than for ANCA-negative and MPO-positive groups combined, with OS higher before age adjustment. PR3-ANCA-positivity independently predicted relapse for all GPA forms combined but not when comparing only PR3-ANCA-positive versus MPO-ANCA-positive patients. CONCLUSIONS: Based on this large cohort, ANCA-negative versus ANCA-positive patients more frequently had limited disease but similar RFS and OS. MPO-ANCA-positive patients had similar RFS but lower OS due to their older age. PR3-ANCA-positive GPA patients' RFS was lower than those of the two other subsets combined but that difference did not persist when comparing only PR3 versus MPO-ANCA-positive patients.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Puéchal X, Iudici M, Pagnoux C, et al. Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. RMD Open. 2022. PMID: 35296533. doi:10.1136/rmdopen-2021-002160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。